UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2017
Commission File Number: 001-36815

Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 5
DK-2900 Hellerup
Denmark
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511 and 333-216882) of Ascendis Pharma A/S (the “Company” or “Ascendis”) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

On April 3, 2017, the Company announced data supporting its product pipeline presented at ENDO 2017, the annual meeting of the Endocrine Society in Orlando, Florida.
TransCon Growth Hormone: Phase 3 Program On Track
TransCon Growth Hormone, with convenient weekly dosing, is designed to release unmodified growth hormone that diffuses freely into the body’s tissues, maximizing its ability to carry out the systemic effects of endogenous and daily growth hormone. It is currently in Phase 3 development as a potential therapy for children with growth hormone deficiency (“GHD”). At ENDO:
 
 	•	 	Two posters described the clinical development program for TransCon Growth Hormone, including results of the pediatric GHD Phase 2 trial, which provided the foundation for the ongoing Phase 3 program.	
 
 	•	 	For the first time, Ascendis researchers also presented data regarding the company’s proprietary auto-injector device, showing that data collected from >70 patients, caregivers and healthcare professionals found the auto-injector easy-to-use. With multiple features designed to create a patient-centric experience, the auto-injector will be used in the extension phase of the heiGHt Trial and is planned to be available for launch of TransCon Growth Hormone.	
TransCon Growth Hormone is being evaluated in the Phase 3 heiGHt Trial, which compares its safety, efficacy and tolerability to daily growth hormone therapy. Ascendis Pharma expects to complete enrollment of the study in the fourth quarter of 2017.
TransCon PTH: A True Potential PTH Replacement Therapy
TransCon PTH is a sustained-release prodrug of parathyroid hormone [PTH(1-34)] for the treatment of hypoparathyroidism, a rare and serious endocrine deficiency disorder that can lead to a variety of neuromuscular, cardiovascular, and other symptoms. It is designed to maintain a steady PTH level within the physiological range over a 24-hour period, helping to address limitations of available therapies.
Two posters at ENDO reviewed the pharmacokinetics and pharmacodynamics of TransCon PTH in animal models:
 
 	•	 	Preclinical data in two separate models demonstrated the infusion-like profile of TransCon PTH following once-daily administration. Studies in healthy monkeys also showed TransCon PTH increased serum calcium while reducing urinary calcium excretion.	
 
 	•	 	In the late-breaking poster, a study in rats who were PTH-deficient following thyroparathyroidectomy showed TransCon PTH normalized serum calcium and phosphorus. This was compared to a higher daily dose of PTH(1-84), a currently available PTH replacement therapy, which did not. Additionally, the data suggested positive effects on bone turnover at evaluated doses.	

Ascendis Pharma plans to initiate a Phase 1 clinical trial of TransCon PTH in the third quarter of 2017.
TransCon CNP Aims to Improve Efficacy and Safety in a Novel Treatment for Achondroplasia
Ascendis scientists presented two posters on TransCon CNP, a sustained-release prodrug of C-Type Natriuretic Peptide, for the treatment of achondroplasia, the most common form of dwarfism:
 
 	•	 	One presentation summarized the pharmacokinetics and lack of adverse hemodynamic effects of TransCon CNP, allowing for the administration of high doses to facilitate optimal efficacy.	
 
 	•	 	A late breaking poster showed a dose-dependent effect on long bone (tibia) growth in juvenile monkeys with weekly TransCon CNP. Following previously presented two-month data at the company’s recent R&D Update, these results demonstrated growth effects continued through six months.	
 
 	•	 	The poster also summarized the effects of TransCon CNP in a mouse model of achondroplasia, including bone growth and the potential to ameliorate some of the more disabling achondroplasia traits, including stenosis of the foramen magnum.	
Ascendis Pharma plans to submit an investigational new drug application or equivalent for TransCon CNP in the fourth quarter of 2017.
Forward-Looking Statements
This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our expectations of completing enrollment of our Phase 3 heiGHt Trial in the fourth quarter of 2017; (ii) whether our proprietary auto-injector device will be available at the launch of TransCon Growth Hormone; (iii) whether TransCon PTH has the potential to become a true PTH replacement therapy; (iv) our expectations of initiating a Phase 1 clinical trial of TransCon PTH in the third quarter of 2017; (v) our plans to submit an investigational new drug application or equivalent for TransCon CNP in the fourth quarter of 2017; (vi) our ability to apply the TransCon technology platform to build a leading rare disease commercial company and (vii) our expectations regarding our ability to create therapies with potential for best-in-class efficacy, safety and/or convenience. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F for the year ended December 31, 2016, which we filed with the SEC on March 22, 2017. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: April 3, 2017
 	 	 	
Ascendis Pharma A/S	
 	 	
By:	 	/s/ Michael Wolff Jensen	
 	 	Michael Wolff Jensen	
 	 	Senior Vice President, General Counsel